Company Overview and News
Following continued requests due to recent earnings, Part 1 of this article analyzes PSEC's dividend sustainability by performing three tests based on recent (and projected) quarterly results.
ARCC MAIN GAIN GAINM GADDP PSEC NEWTZ ARU MSCA.CL SLRC MSCA TSLX NEWT NEWTL PBB SLRA MO
It's your September 2018 Monthly-Paid (MoPay) Small-Mid-Large Cap Dividend, Yield, Upsides, and Net Gains Report. Nano-Cap MoPays <$200M are not listed.
CRLFF CRIUF ORC MHIVF GLADO ATGFF AGNC TRSWF KWH.UN PSEC SCQ PBB MGRUF SCA CJ GOOD OXLCO OXLCN SCM GOODM GLAD SOT.UN RNW GOODN ECC ECCZ AHOTF ECCY GOODO GOODP SRRTF ARESF CGIFF PZRIF ?NHF? OXLC ECCB ARR ECCA SUNS GNL NHF ALA SRT.UN PZA
I recently purchased additional shares of this higher quality BDC that's trading 6% below book value paying a 9% dividend yield with an upcoming special dividend in Q4.
AIY AINV CLA MCQ KAP PNNT BKCC MCV PFLT OSLE CGBD GLADO HTGZ KCAP GLAD ABDC CPTA MCC TCRX ARCC HCAPL FSIC TCPC AIB TCRD TCRZ PSEC HTGX NMFC TSLF HTGY OCSI ARU OCSL MCX HCAP SUNS HTGC PBB PNTA
Launched on 02/11/2013, the VanEck Vectors BDC Income ETF (BIZD - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Financials - BDCs/PE segment of the equity market.
ARU MSCA.CL ARKG ARCC MSCA MAIN AMZA PBB PSEC ARKK
Part 2 of this article compares MAIN’s recent dividend per share rates, yield percentages, and several other dividend sustainability metrics to fourteen other BDC peers.
AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ ARU OCSL MSCA.CL MCX BLK MDLY NEWTL PBB
Franklin Resources’ (BEN - Free Report) shares have dropped 25.9% in the past year compared with the industry’s decline of around 2%, on rising investors’ concerns due to persistent net outflows recorded by the company. Investment management fees have been Franklin’s biggest source of revenues, comprising about 68%, for the past few years. Notably, during fiscals 2016 and 2017, fees declined due to reduction in average assets under management (AUM) and lower effective fee rate, which remain concerns.
LAZ BEN NOAH PBB PSEC
Prospect Capital Corporation (PSEC - Free Report) is a financial services company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
CY PBB PSEC
The Carlyle Group L.P. (CG - Free Report) plans to phase out its Chinese real estate team by the end of this year, per a report by Bloomberg. The company, which has been trying to revamp its Asian Unit, has decided to shift its focus from the Chinese real estate market due to decline in investors’ interest for country-specific funds. Notably, the company made key changes in its executive leadership team in 2017, which got into effect from Jan 1, 2018.
AMP LAZ CG PBB PSEC
Following multiple requests, this “supplemental” article compares PSEC’s recent quarterly change in NAV, quarterly and trailing twelve-month economic return, NII, and current valuation to 14 BDC peers.
AIY AINV GAIN MCQ GAINM MCV PFLT OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC MAIN TCPC AIB PSEC NEWTZ ARU OCSL MSCA.CL MCX BLK NEWTL PBB
On 8/28/2018, PSEC reported results for the fiscal fourth quarter of 2018. PSEC reported NII, earnings, and a NAV as of 6/30/2018 of $0.219, $0.315, and $9.349 per share, respectively.
MSCA.CL MSCA MAIN TSLX PBB PSEC MO
This article compares the return and expense ratios for the BDC sector so that investors can identify which companies are efficiently able to distribute higher returns to shareholders.
CLA MCQ MRCC MCV PFLT OSLE HTGZ ABDC MSCA TSLX CPTA MCC GSBD TCRX GBDC MAIN TCRD TCRZ PSEC HTGX TSLF HTGY OCSI OCSL MSCA.CL MCX SUNS HTGC PBB
Lazard Ltd. (LAZ - Free Report) is well positioned to benefit from a healthy combination of organic and inorganic growth. Its cost-containment measures are also expected to boost the company’s long-term profitability, moving ahead. However, heavy reliance on overseas revenues might impede top-line growth. The company’s shares have gained 10.7% over the past year compared to the industry’s decline of 0.
AMP LAZ PBB AB PSEC
2018-08-31 seekingalpha - 1
22 of 69 Monthly Paying (MoPay) U.S. dividend stocks were tagged "safer" by showing positive annual returns, and free cash flow yields greater than their dividend yields as of 8/27/18.
AGNCB CMLEF CLA APLE BTBIF FSC ORC PMULF OSLE PSEC SJT OCSL CWYUF FSCFL AGNCP AGNC CPTA PBB STAG FSCE
Prospect Capital Corp. (PSEC) released a solid deck of financials for its fourth fiscal quarter this week that caused the BDC's stock price to break out to the upside. Prospect Capital Corp. currently offers income investors a dividend yield that is covered by net investment income. The BDC's shares today sell for a 20 percent discount to the last reported net asset value. I currently rate PSEC as a "Hold".
17h - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
17h - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
19h - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET